Multiple Myeloma

Using patient data, a predictive algorithm can identify the risk of progression to multiple myeloma in those with asymptomatic precursor conditions. This algorithm can help clinicians decide when to initiate treatment and which patients require closer monitoring. People with multiple myeloma precursor conditions are likely to develop symptomatic multiple myeloma. Predicting the disease severity of...

Patients with rapidly progressing multiple myeloma showed distinct overexpression of genetic markers related to cancer-facilitating cellular activity. This study sheds light on the variations in disease progression and paves the way for personalized treatment strategies. Multiple myeloma is an aggressive cancer with a low survival rate. Some patients experience more rapid disease progression than others....

Although about 18% of patients with multiple myeloma in the United States are Black, they represent only 4% of clinical trial participants. This article describes why this occurs, what the consequences are, and how this situation can be remedied This article, published in Blood Advances, describes the demographic representation in multiple myeloma (MM) clinical trials....

The way that multiple myeloma cells distribute throughout the body can relate to treatment types and disease progression in various ways. Imaging can be a robust source of useful information in these cases. This article, published in Nature Communications, attempts to address the evolution of multiple myeloma (MM) in whole bone marrow, in order to...

Although multiple myeloma cannot be cured, treatments are available to help improve symptoms and manage quality of life. However, while treatments can help control the disease, mortality remains a concern for patients with multiple myeloma and their healthcare providers. Little research has been conducted on end-of-life care for multiple myeloma patients. This retrospective population-based cohort...

African Americans tend to have a higher risk of developing multiple myeloma at an earlier age and a higher risk of death than whites. While certain factors, such as socioeconomic status and access to care, can affect the outcomes of multiple myeloma, there’s no question that genetic mutations may also play a significant role in...

Multiple myeloma can affect different racial groups in different ways, especially since clinical trials are often skewed without equal representation. For example, around 20% of people affected by multiple myeloma are Black, but only 6% of participants in multiple myeloma clinical trials are Black.  This study, published in the Journal of Clinical Oncology for the 2022 ASCO...

According to the International Myeloma Foundation, there are key differences in how multiple myeloma presents in African Americans compared to people of other ethnicities. First, African Americans tend to have an earlier age of onset of the disease. Second, monoclonal gammopathy of undetermined significance (MGUS), a precancerous condition that can progress to multiple myeloma, is...

Many researchers have observed a disparity in overall survival between non-Hispanic Black Americans and non-Hispanic white Americans with multiple myeloma. However, the clinical characteristics and overall survival of Hispanic Americans with the disease remain unknown. This analysis aimed to characterize multiple myeloma in Hispanic Americans. A total of 939 patients were analyzed, with all patients...